Skip to content
Subscriber Only
Opinion
Max Nisen

Biotech Deals Will Bounce Back in 2017

Despite uncertainties, M&A fundamentals are improving.

Biotech could really use the clean slate of a New Year. The Nasdaq Biotech Index collapsed 28 percent in the opening weeks of 2016 and never fully recovered, ending the year down about 22 percent. 

One of the culprits has been a slowdown in big-time M&A -- particularly damaging for a sector that needs deal speculation to boost the share prices of companies years away from actually marketing a drug.